An interventional study of Group A and Group B in Blepharitis, sponsored by University of Cologne. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2018-11-19.
Sponsored by University of Cologne · Not applicable, Interventional, and Treatment
The aim of the study is to compare the effectiveness in treatment of chronic blepharitis either with a phospholipid liposome suspension compared to a conventional therapy recommendation using diluted baby shampoo.
73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.
This study's enrollment of 144 is above the median of 60 across 65 interventional studies indexed under Blepharitis.
Browse Blepharitis studies →University of Cologne is the lead sponsor of 203 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with chronic blepharitis, that will be treated with blephacura
Procedure: Group A
Patients with chronic blepharitis that will be treated with diluted baby shampoo
Procedure: Group B
Blephacura is a solution with liposomes and used for cleaning of the eye lid to treat blepharitis
Diluted Baby Shampoo is used for cleaning of the eye lid to treat blepharitis
Ran from May 2010 to primary completion in Dec 2010, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.